Hepatocellular carcinoma in the native liver of a 38-year-old female patient with biliary atresia

Yutaka Kanamori, Masataka Takahashi, Reiko Ito, Katsuhiro Arai, Sachi Koinuma, Yuko Okinaga, Kiyoshi Hasegawa, Norihiro Kokudo

Division of Surgery, Department of Surgical Specialty, National Center for Child Health and Development, Japan
Division of Gastroenterology, Department of Medical Subspecialty, National Center for Child Health and Development, Japan
Japan Drug Information Institution, National Center for Child Health and Development, Japan
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Japan

Article info
Article history:
Received 7 August 2015
Received in revised form 30 September 2015
Accepted 30 September 2015

Key words:
Biliary atresia
Hepatocellular carcinoma
Cholangitis

Abstract
We report a rare case of hepatocellular carcinoma in native liver in a case of biliary atresia. The patient was a 38-year-old female with three children who had an aggressive tumor, resulting in her subsequent death. We also review 14 reports, published previously in the English language medical literature, concerning hepatocellular carcinoma originating from native liver in biliary atresia cases and discuss the possible etiology, and propose more careful follow up for the patients with biliary atresia who suffer from repetitive cholangitis and/or experience the child delivery.

Hepatocellular carcinoma (HCC) is rarely seen in cirrhotic liver of biliary atresia, with only 20 cases having been reported in the English language medical literature [1–14]. Almost all hepatocellular carcinomas seen in biliary atresia are slow growing and not very aggressive tumors, with half of them incidentally found in extracted livers at autopsy or after liver transplantation.

Here we report on a 38-year-old female patient with biliary atresia, who had long suffered from repetitive cholangitis and finally died of a hepatocellular carcinoma in her native liver.

1. Case
A 38-year-old female patient was referred to our department because an hepatic tumor was suspected after a high serum alpha-fetoprotein (AFP) level, and as subsequently demonstrated by abdominal computed tomography (CT) scan. She had previously been admitted to our institute because of prolonged jaundice during her early infantile years. As a 71-days-old baby, after several examinations, the patient was diagnosed with biliary atresia type III and underwent portoenterostomy with a bile drainage stoma. After the operation, her jaundice subsided and since then, she has been followed at our outpatient clinic. Periodic blood tests showed mild liver dysfunction and she underwent splenectomy at 24 years of age because of worsening hypersplenism caused by prolonged portal hypertension. The patient had borne three children, delivering them at 30, 35, and 38 years of age. She was followed at our outpatient clinic every three months and at 38 years of age abdominal ultrasound were taken and a hepatic mass, 3 cm in diameter, was found in the posterior segment of the right lobe (Fig. 1a) which was first thought to be focal nodular hyperplasia. But a blood test showed a high AFP level (2632.8 ng/mL). The mass grew rapidly to 6 cm by two weeks which was ascertained by abdominal CT scans, and hepatocellular carcinoma was strongly suspected (Fig. 1b and c). Serological tests were negative for hepatitis B antigen and hepatitis C antibody. A month later, a laparotomy revealed a bloody ascites in the abdominal cavity, which suggested a spontaneous rupture of the tumor. The posterior segment of the right lobe (Fig. 2a) was resected and the tumor was macroscopically removed. The pathological diagnosis was a moderately differentiated hepatocellular carcinoma (Fig. 2b and c); background liver tissue showed severe
Fig. 1. (a) An abdominal ultrasound examination demonstrated a mass of 3.0 cm diameter in the right lobe of the liver. (b) Two weeks later, an abdominal CT scan showed the mass in the liver had grown rapidly to a diameter of 6.0 cm. Arterial phase imaging revealed the mass to have an enhanced margin. (c) An abdominal CT of the venous phase showed a relatively contrasting mass with low density. These results strongly suggested the mass was a hepatocellular carcinoma.

Fig. 2. (a) Intraoperative photo of the tumor. The tumor had ruptured and was sited in the posterior segment of the right liver. Segment 1 (caudate lobe) was very hypertrophic. (b) Macroscopic appearance of the tumor, which was well encapsulated, but partially necrotic and ruptured. (c) Microscopic findings revealed that the tumor was a moderately differentiated, hepatocellular carcinoma.

Fig. 3. (a) Tumor recurrence was detected in the caudate lobe of the liver, which was found to be extremely hypertrophic, three months after the first operation. The tumor was resected in a second operation. The arrow indicates the middle hepatic vein. (b) The tumor recurred after a second operation. Its growth could not be controlled by chemotherapy combined with Sorafenib.
fibrosis and a paucity of bile ducts. Three months later, a recurrence of the tumor was detected in hypertrophic segment 1, which was subsequently resected again (Fig. 3a). After the second operation, the persistence of a high fever was noted, together with multiple lung metastases as demonstrated by lung CT scans; tumor recurrence was also demonstrated in the residual liver. Sorafenib was administered but tumor progression could not be controlled (Fig. 3b), and a year after the first operation, the patient died after tumor rupture and hepatic failure.

2. Discussion

Hepatocellular carcinoma is relatively rare in childhood and is often seen in cirrhotic liver with chronic viral hepatitis. Conversely, HCC is rarely seen in liver with biliary atresia, with only 20 cases previously reported in the English language medical literature [1–14] (Table 1). Our case is the twenty-first case to be reported. Briefly in summary, five out of the 20 HCC in biliary atresia cases had been autopsied [1–4,7], and reported in the days prior to the liver transplantation era. Of the 20 cases, eight were male and 11 were female, with one of unknown sex, and all were under the age of 20. AFP was elevated in 10 out of 15 cases, including our reported case [5,7,9,10,12,13]. Given the data on chronic viral infection, such as hepatitis B or hepatitis C, is quite restrictive, only three cases were checked for infection, including our case, and all were found to be negative [7,11]. Liver transplantation was successfully performed in 15 cases. In 10 cases, including autopsied cases, HCC was incidentally found in the liver.

Our case is strikingly uncharacteristic for HCC in biliary atresia in some respects: for instance, tumor growth was very rapid and aggressive, which was quite different from that of previously reported cases. The patient was followed every three months with abdominal CT or MRI be recommended. The persistence of a high fever was noted, together with multiple lung metastases as demonstrated by lung CT scans; tumor recurrence was also demonstrated in the residual liver. Sorafenib was administered but tumor progression could not be controlled (Fig. 3b), and a year after the first operation, the patient died after tumor rupture and hepatic failure.

3. Conclusion

A 38-year-old patient with biliary atresia could not be saved because of an extremely aggressive HCC, in spite of periodic follow-up. Recently, the number of long-term survivors of biliary atresia in native liver has increased. However, the establishment of follow-up schedules in these patients are lacking. Our case is a valuable lesson for considering such a scheme in future. We now recommend more careful follow up for the patients with biliary atresia who suffer from repetitive cholangitis and/or experience the child delivery. To be more concrete, periodic AFP measurement and ultrasound examination are important and once AFP elevation appears the early abdominal CT or MRI be recommended.

References


Table 1

Hepatocellular carcinoma in native liver of biliary atresia.

<table>
<thead>
<tr>
<th>Case</th>
<th>Gender</th>
<th>Age</th>
<th>AFP</th>
<th>HBsAg/HCVAb</th>
<th>Diagnosis</th>
<th>Tx</th>
<th>Status</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>3y</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>None</td>
<td>Dead (autopsy)</td>
<td>[1]</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>5m</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>None</td>
<td>Dead (autopsy)</td>
<td>[2]</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>2y</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>None</td>
<td>Dead (autopsy)</td>
<td>[3]</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>6y</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>None</td>
<td>Dead (autopsy)</td>
<td>[4]</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>12y</td>
<td>+</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[5]</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>4y</td>
<td>+</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[5]</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>6y</td>
<td>+</td>
<td>–/-</td>
<td>Liver mass</td>
<td>Ethanol injection</td>
<td>Dead</td>
<td>[7]</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>12y</td>
<td>+</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[8]</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>8y</td>
<td>+</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[9]</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>10y</td>
<td>–</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[9]</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>11y</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[6]</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>4y</td>
<td>–</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[13]</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>2y</td>
<td>+</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[13]</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>1y</td>
<td>+</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[13]</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>17y</td>
<td>–</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[13]</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>1y</td>
<td>–</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[13]</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>10m</td>
<td>–/-</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[12]</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>8m</td>
<td>+</td>
<td>NA</td>
<td>Liver mass</td>
<td>LTx</td>
<td>Alive</td>
<td>[10]</td>
</tr>
<tr>
<td>20</td>
<td>F</td>
<td>10m</td>
<td>NA</td>
<td>NA</td>
<td>Incidental</td>
<td>LTx</td>
<td>Alive</td>
<td>[14]</td>
</tr>
<tr>
<td>21</td>
<td>F</td>
<td>38y</td>
<td>+</td>
<td>–/-</td>
<td>Liver mass</td>
<td>Tumor resection</td>
<td>Dead</td>
<td>Our case</td>
</tr>
</tbody>
</table>

Tx: treatment for the tumor, HBsAg: hepatitis B antigen, HCVAb: hepatitis C antibody, NA: not available, LTx: liver transplantation.
References